Biomedical Engineering Reference
In-Depth Information
[48] ICH. M4Q: The CTD—Quality, 2001. http://www.fda.gov/cder/guidance/4539q.pdf.
[49] U.S. FDA. Pharmaceutical Quality for the 21st Century: A Risk-Based Approach Progress
Report, 2007. http://69.20.19.211/oc/cgmp/report0507.html#appendix17.
[50] EFPIA. Mock P2 for “Examplain” Hydrochloride, 2006. http://www.efpia.org/content/
default.asp?PageID
¼
263&DocID
¼
2933.
[51] Chen C. CMC Pilot Program: What are the Best Practices for Quality Assessment: an FDA
Perspective. Roundtable on Challenges and Opportunities for Implementation of Quality by
Design (QbD). Meeting, AA. San Diego, CA; 2007.
[52] U.S. FDA. Minutes for October 5, 2006 Meeting, Advisory Committee for Pharmaceutical
Science, 2006.
[53] Winkle HN. Implementing Quality by Design. Evolution of the Global Regulatory Environ-
ment: A Practical Approach to Change, 2007. http://www.fda.gov/Cder/OPS/Implemen-
tingQualitybyDesign.pdf.
[54] CFR. Title 21 Changes to an approved application: Protocols. 601.12(e), 2006.
[55] CFR. Title 21 Supplements and other changes to an approved application: Protocols. 314.70
(e), 2006.
[56] Kozlowski S. Protein therapeutics and the regulation of quality: a brief history from an OBP
perspective. BioPharm Int 2007;20(10):37-55.
